Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
View Patent ↗The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.
1. An isolated biopolymer marker peptide consisting of amino acid residues 2–11 of SEQ ID NO:1 diagnostic for myocardial infarction, congestive heart failure or intracerebral hemorrhage.
2. A method for diagnosing myocardial infarction, congestive heart failure or intracerebral hemorrhage comprising:
(a) obtaining a sample from a patient;
(b) preparing said sample to maximize the diversity of biopolymers discernible from said sample;
(c) conducting mass spectrometric analysis on said sample; and
(d) comparing mass spectrum profiles of a peptide consisting of amino acid residues 2–11 of SEQ ID NO:1 to mass spectrum profiles of biopolymers discerned from said sample; wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of amino acid residues 2–11 of SEQ ID NO:1 is diagnostic for myocardial infarction, congestive heart failure or intracerebral hemorrhage.
3. The method of claim 2 , wherein the sample is an unfractionated body fluid or a tissue sample.
4. The method of claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.
5. The method of claim 2 , wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).
6. The method of claim 2 , wherein said patient is a human.
7. A kit for determining the presence of an isolated biopolymer marker peptide consisting of amino acid residues 2–11 of SEQ ID NO:1 comprising: (a) an isolated biopolymer marker peptide consisting of amino acid residues 2–11 of SEQ ID NO:1 and (b) an antibody that binds to said peptide in a sample from a patient.
8. The kit of claim 7 , wherein said antibody is immobilized on a solid support.
9. The kit of claim 7 , wherein said antibody is labeled.